CommercialCoverageMedium impact
08.01.94d, Nivolumab and Relatlimab-rmbw (Opdualag™) for intravenous use
Independence Blue Cross·Oncology, Hematology·Pharmacy
Effective date
Mar 4, 2026
We identified it
Jun 19, 2026
Summary
The Nivolumab and Relatlimab-rmbw (Opdualag™) intravenous therapy policy has been reissued for commercial plans. This policy governs coverage and billing requirements for this cancer immunotherapy combination drug administered intravenously.
Action Required
By March 4, 2026: Billing team should review the full policy document at the provided URL to understand specific coverage criteria, prior authorization requirements, and billing guidelines for Nivolumab and Relatlimab-rmbw (Opdualag™) infusions. Update billing procedures and staff training materials accordingly for commercial plan patients receiving this cancer therapy.